Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.
One area to focus on is companies that generally offer steady earnings growth over time. CRISPR Therapeutics (NASDAQ: CRSP) just reached a huge milestone, and another may be just ahead. The company recently won the world's first authorization for a CRISPR-based gene-editing treatment when the U.K. gave the nod to exa-cel (to be commercialized as Casgevy).
U.S. stocks rallied and the S&P registered its highest close of the year on Friday, starting December on an upbeat note as remarks from Federal Reserve Chair Jerome Powell bolstered the view that key policy rates have peaked. All three major U.S. stock indexes advanced, with economically sensitive transports and smallcaps enjoying the most robust gains. "Those sectors - the cyclicals - they're the most hated parts of the market year-to-date, (and they) are the parts that are leading," said Scott Ladner, chief investment officer at Horizon Investments in Charlotte, North Carolina.